Strategy Shifting Strategy Shifting
to the Transformation Transformation
S tr a te g y S h ift in g S tr a te g y S h ift in g to t h e T ran sf o rm a tio n T ran sf o rm a tio n
Peralihan Strategi Menuju Transformasi
Peralihan Strategi Menuju Transformasi
Sanggahan dan Batasan Tanggung Jawab
Disclaimer
Laporan Tahunan untuk tahun buku 2022 yang disajikan oleh PT Indofarma Tbk berisi pernyataan berupa kondisi keuangan, hasil operasional, kebijakan strategis, proyeksi, serta tujuan Perseroan yang dijalankan selama satu tahun yang mengacu pada peraturan perundang- undangan yang berlaku. Pernyataan tersebut memiliki prospek risiko serta ketidakpastian karena informasi yang disajikan bersifat dinamis sesuai dengan aktualisasi perkembangan pada kondisi bisnis secara global, nasional, maupun dalam industri.
Pernyataan-pernyataan tersebut dibuat berdasarkan asumsi yang diperoleh setelah melakukan kajian yang rinci terhadap kondisi Perseroan terkini dan di masa yang akan datang. Perseroan tidak menjamin bahwa dokumen-dokumen yang telah dipastikan keabsahannya akan membawa hasil tertentu sesuai harapan.
Dalam Laporan Tahunan 2022 ini, kata “Perseroan” atau
“Indofarma” digunakan untuk menyebut PT Indofarma Tbk selaku perusahaan yang bergerak dalam bidang industri healthcare. Adapun kata “Kami” juga digunakan atas dasar kemudahan dalam penyebutan PT Indofarma Tbk secara umum.
The Annual Report for the 2022 financial year presented by PT Indofarma Tbk contains statements of financial conditions, operational results, strategic policies, projections, and the objectives of the Company to be carried out for one year referring to the prevailing laws and regulations. This statement has prospects of risk and uncertainty because the information presented is dynamic in accordance with actual developments in global, national, and industry business conditions.
These statements are made based on assumptions obtained after conducting a detailed study of the Company's current and future conditions. The Company does not guarantee that documents whose validity has been confirmed will bring certain results as expected.
In this 2022 Annual Report, the words "Company" or
"Indofarma" are used to refer to PT Indofarma Tbk as a company engaged in the healthcare industry.
While the word "We" is also used on the basis of convenience in referring to PT Indofarma Tbk in general.
Tentang Laporan Tahunan 2022
About the 2022 Annual Report
Tema Laporan Tahunan 2022 yang diusung PT Indofarma Tbk (selanjutnya disebut “Perseroan”
atau “Indofarma”) adalah “STRATEGY SHIFTING TO THE TRANSFORMATION”. Tema tersebut mewakili keinginan besar Indofarma dalam melanjutkan pencapaian dan prestasi yang telah diraih untuk kemudian menjadi penggerak menuju perubahan yang baru, sehingga dapat mewujudkan kinerja yang memiliki daya saing kuat sekaligus membawa pertumbuhan berkelanjutan.
The theme for the 2022 Annual Report carried by PT Indofarma Tbk (hereinafter referred to as “The Company” or “Indofarma”) is “STRATEGY SHIFTING TO THE TRANSFORMATION”. This theme represents Indofarma's excessive desire to continue the achievements and realizations that have been attained to then become the drive for the new transformation, hence to generate strong competitiveness performance while bringing the sustainable growth.
Strategy Shifting Strategy Shifting
to the Transformation Transformation
Peralihan Strategi
Menuju Transformasi
Daftar Isi
Table of Contents
Pendahuluan Introduction
Sanggahan dan Batasan Tanggung Jawab
Disclaimer 02
Tentang Laporan Tahunan 2022
About the 2022 Annual Report 03
Daftar Isi
Table of Contents 04
Kilas Kinerja 2022
2022 Performance Highlights
Ikhtisar Data Keuangan Penting
Key Financial Highlights 10
Grafik Keuangan Penting
Key Financial Charts 12
Ikhtisar Kinerja Operasional
Operational Performance Highlights 14
Ikhtisar Saham
Share Highlights 14
Aksi Korporasi
Corporate Action 15
Informasi Penghentian Sementara dan/atau Sanksi Perdagangan Saham Inaf
Information on Suspension and/or Trade Sanction of Inaf Shares
15
Ikhtisar Obligasi, Sukuk, dan/atau Obligasi Konversi
Bonds, Sukuk and/or Convertible Bonds Overview 16
Informasi Sumber Pendanaan Lainnya
Information on Other Financing Sources 16
Penghargaan
Awards 17
Peristiwa Penting
Significant Event 18
Laporan Manajemen Management Report
Laporan Dewan Komisaris
The Board of Commissioners’ Report 26
Laporan Direksi
The Board of Directors’ Report 34
Surat Pernyataan Anggota Direksi dan Dewan Komisaris Tentang Tanggung Jawab Atas Laporan Tahunan 2022
Statement of Members of The Board of Directors and Board of Commissioners on Responsibility for The 2022 Annual Report
40
Profil Perusahaan Company Profile
Informasi Umum Perusahaan
General Information of The Company 44
Riwayat Singkat Perusahaan
Company’s Brief History 46
Visi, Misi, dan Budaya Perusahaan
Vision, Mission, and Corporate Culture 56
Makna Logo Perusahaan
Company Logo Signification 59
Bidang Usaha
Line of Businesses 60
Produk dan Jasa Perusahaan
Company Products and Services 62
Jaringan Operasional Perusahaan
Company’s Operational Network 66
Alamat dan Kontak Dari Jaringan Operasional Perusahaan
Company Operational Network Addresses and Contacts
68
Profil Dewan Komisaris
Board of Commissioners 70
Profil Direksi
Board of Directors Profile 74
Struktur Organisasi Perusahaan
Organizational Structure 78
Profil Sumber Daya Manusia Perusahaan
Company Human Resources Profile 80
Struktur Grup Perusahaan
Company’s Group Structure 85
Kronologi Pencatatan Saham
Share Listing Chronology 86
Komposisi Pemegang Saham
Shareholder Composition 88
Informasi Pemegang Saham Utama dan/atau Pengendali
Information on Majority and/or Controlling Shareholders
89
Informasi Entitas Anak, Entitas Asosiasi, Perusahaan Joint Venture (JV), dan/atau Special Purpose Vehicle (SPV)
Information of Subsidiaries, Associates, Joint Venture (JV), and/or Special Purpose Vehicle (SPV)
90
Kronologi Penerbitan dan/atau Pencatatan Efek Lainnya
Chronology of Issuance and/or Listing of Other Securities
95
Lembaga dan/atau Profesi Penunjang Pasar Modal
Capital Market Supporting Institutions/
Professionals
96
Daftar Keanggotaan Asosiasi
Association Membership 96
Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Tinjauan Umum
General Overview 100
Tinjauan Industri Farmasi dan Alat Kesehatan Pharmaceutical dnd Medical Devices Industry
Overview 102
Strategi Usaha
Business Strategy 105
Aspek Pemasaran
Marketing Aspect 109
Tinjauan Operasi Per Segmen Usaha
Operational Overview Per Business Segment 114
Tinjauan Keuangan
Financial Overview 135
Kemampuan Membayar Utang
Ability To Pay Debt 145
Kolektabilitas Piutang
Accounts Receivable Collectability 147
Struktur Modal dan Kebijakan Manajemen atas Struktur Modal
Capital Structure and Management Policy on Capital Structure
149
Ikatan Material untuk Investasi Barang Modal Material Bonds for Capital Good Investment 151
Investasi Barang Modal
Capital Good Investment 151
Informasi dan Fakta Material yang Terjadi Setelah Tanggal Laporan
Material Information and Facts Occurring After The Report Date
152
Dampak Nilai Tukar Mata Uang Asing
Impact of Foreign Exchange Rate 153
Prospek Usaha
Business Prospect 154
Perbandingan Antara Target dan Realisasi Tahun 2022
Comparison Between Target and Realization in Between 2022
155
Proyeksi Tahun 2023
Projection for 2023 157
Kebijakan dan Pembagian Dividen
Dividend Policy and Payment 159
Program Kepemilikan Saham oleh Karyawan dan/ atau Manajemen (ESOP/ MSOP)
Employee and/or Management Share Ownership Program (ESOP/ MESOP)
160
Realisasi Penggunaan Dana Hasil Penawaran UmumUse of Proceeds from Public Offerings 160
Informasi Material Mengenai Investasi, Ekspansi, Divestasi, Penggabungan Usaha, Akuisisi, dan/atau Restrukturisasi Utang/Modal Material Information Regarding, Investment Expansion, Divestment, Merger, Acquisition, and/or Debt/ Capital Restructuring
161
Informasi Transaksi Material yang
Mengandung Kepentingan/atau Transaksi Dengan Pihak Afiliasi/ Pihak Berelasi Information on Material Transaction Containing Conflicts Of Interest and/or Transaction Affilliated/Related Parties
161
Nama Pihak, Sifat Hubungan dan Jenis Transaksi, Serta Nilai Transaksi Dengan Pihak Berelasi
Name of Transaction Party, Nature of Affiliation Relationship, and Reasons for The Transaction
162
Informasi Keuangan yang Mengandung Kejadian yang Bersifat Luar Biasa dan Jarang Terjadi
Financial Information Containing Extraordinary and Rare Events
166
Perubahan Peraturan Perundang-Undangan yang Berpengaruh Signifikan Terhadap Perseroan
161 Change to Laws and Regulation with Significant Impact to The Company
166
Perubahan Kebijakan Akuntansi dan Dampaknya Terhadap Perseroan 162 Change in Accounting Policy and its Impact on The Company
167
Kelangsungan Usaha
Business Continuity 167
Tata Kelola Perusahaan Good Corporate Governance
Komitmen Penerapan GCG
GCG Implementation Commitment 176
Pemegang Saham dan Rapat Umum Pemegang Saham
Shareholders and General Meeting of Shareholders
193
Dewan Komisaris
Board of Commissioner 215
Direksi
Board of Director 250
Remunerasi Dewan Komisaris dan Direksi Remuneration of The Board of Commissioners
and Board of Directors 280
Organ Pendukung Dewan Komisaris
Supporting Organs of Board of Commissioners 287
Komite Audit
Audit Committee 293
Komite GCG & Pemantauan Risiko
GCG & Risk Monitoring Committee 310
Komite Nominasi dan Remunerasi
Nomination and Remuneration Commitee 325
Organ Pendukung Direksi
Supporting Organs of Board of Directors 346
Sekretaris Perusahaan
Corporate Secretary 347
Audit Internal/Satuan Pengawasan Intern
Internal Audit/Internal Audit Unit 357
Komite di Bawah Direksi
Committees Under The Board of Directors 371
Audit Eksternal/Akuntan Publik
External Audit/Public Accountant 374
Manajemen Risiko
Risk Management 380
Sistem Pengendalian Internal
Internal Control System 397
Tata Kelola Teknologi Informasi
Information Technology Governance 405
Akses Informasi dan Data Perusahaan
Access to Information and Corporate Data 414
Perkara Penting dan Sanksi Administrasi
Significant Cases and Administrative Sanction 421
Kode Etik Perusahaan
Code of Conduct and Corporate Culture 423
Sistem Manajemen Anti Penyuapan ISO 37001:2016
Anti –Bribery Management System ISO 37001:2016
431
Whistleblowing System
Whistle Blowing Sysyem 433
Pengendalian Gratifikasi
Gratification Control 440
Laporan Harta Kekayaan Penyelenggara Negara (LHKPN)
Report of The State Official’s Wealth (LHKPN) 447
Penilaian Evaluasi Good Corporate Governance Good Corporate Governance (GCG) Assessment
& Evaluation 452
Penilaian Kriteria Penilaian Kinerja Unggul (KPKU)
Superior Performance Appraisal Criteria Assessment
489
Tanggung Jawab Sosial Perusahaan Corporate Social Responsibility
Tanggung Jawab Sosial dan Lingkungan Perusahaan
Corporate Social and Enviromental Responsibility
492
Perumusan Tanggung Jawab Sosial dan
Tanggung Jawab Terhadap Pemenuhan Hak Asasi Manusia
Responsibility on The Fulfillment of Human Rights
501
Tanggung Jawab Operasi yang Adil
Responsibility in Fair Operations 504
Tanggung Jawab Lingkungan Hidup
Environmental Responsibility 507
Tanggung Jawab Ketenagakerjaan, Kesehatan, dan Keselamatan Kerja (K3)
Responsibility on Manpower, Occupational Health, and Safety (OHS)
522
Tanggung Jawab Terhadap Mitra Kerja dan Konsumen
Responsibility to Business Partners and Consumers
535
Rumusan Pendekatan Keberlanjutan Aspek Pengembangan Potensi Masyarakat
Formula of Sustainability Approach Aspects of Community Potential Development
543
Tanggung Jawab Pengembangan Masyarakat Responsibility to Community Development 544
Rincian Program Bantuan Perseroan Sepanjang Tahun 2022
Information of The Company Assistance Program Throughout 2022
547
Laporan Keuangan Financial Report
Kilas Kinerja 2022
2022 Performance Highlights
Ikhtisar Data Keuangan Penting
Key Financial Highlights
Laporan Posisi Keuangan Konsolidasian
Consolidated Statements of Financial Position
(Dalam jutaan Rupiah | In million Rupiah) Uraian
Description 2022 2021 2020 2019 2018
Aset Lancar
Current Assets 863.577 1.411.390 1.134.732 829.103 867.493
Investasi pada Entitas Asosiasi
Investment in Associate 1.300 1.215 1.115 741 462
Aset Tidak Lancar
Non-Current Assets 670.423 600.489 578.601 554.831 574.857
Jumlah Aset
Total Assets 1.534.000 2.011.879 1.713.334 1.383.935 1.442.350
Liabilitas Jangka Pendek
Current Liabilities 985.245 1.045.188 836.751 440.827 827.237
Liabilitas Jangka Panjang
Non-Current Liabilities 462.405 458.381 446.256 438.172 118.465
Jumlah Liabilitas
Total Liabilities 1.447.651 1.503.569 1.283.008 878.999 945.703
Jumlah Ekuitas
Total Equity 86.348 508.309 430.326 504.935 496.646
Jumlah Liabilitas dan Ekuitas
Total Liabilities and Equity 1.534.000 2.011.879 1.713.334 1.383.935 1.442.350
Laporan Laba (Rugi) dan Penghasilan Komprehensif Lain Konsolidasian
Consolidated Statement of Profit (Loss) and Other Comprehensive Income
(Dalam jutaan Rupiah | In million Rupiah) Uraian
Description 2022 2021 2020 2019 2018
Penjualan Bersih
Net Sales 1.144.108 2.901.987 1.715.588 1.359.175 1.592.980
Beban Pokok Penjualan
Cost of Goods Sold (1.254.217) (2.450.333) (1.314.988) (1.108.815) (1.308.760) Laba Bruto
Gross Profit (110.109) 451.654 400.600 250.360 284.220
Laba (Rugi) Usaha
Operating Profit (Loss) (479.544) 51.979 58.169 50.055 25.910
Manfaat (Beban) Pajak Penghasilan
Benefit (Expense) of Deffered Tax 89.070 (46.344) (18.051) (1.784) (7.438)
(Dalam jutaan Rupiah | In million Rupiah) Uraian
Description 2022 2021 2020 2019 2018
Kepentingan non-pengendali
Non-Controlling Interest (25) 9 2 1 (0,58)
Laba Komprehensif yang Dapat Diatribusikan kepada Comprehensive Profit Attributable to:
Pemilik Entitas Induk
Owners of the Parent (421.937) (28.823) (3.632) 8.287 (29.762)
Kepentingan non-pengendali
Non-Controlling Interest (25) 9 2 0,99 (0,57)
Laba (Rugi) Bersih per Saham (dalam Rupiah penuh)
Net Profit (Loss) per Share (in full Rupiah)
(138,25) (12,12) 0,01 2,57 (10,56)
Rasio-Rasio Keuangan
Financial Ratios
Uraian
Description 2022 2021 2020 2019 2018
Rasio Likuiditas Liquidity Ratio Rasio Lancar Current Ratio (%)
87,65 135,04 135,61 188,08 104,87
Rasio Kas Cash Ratio (%)
27,38 36,43 18,90 34,34 15,63
Rasio Solvabilitas Solvency Ratio
Rasio Liabilitas terhadap Ekuitas Liability to Equity Ratio (%)
1.676,51 295,80 298,15 174,08 190,42
Rasio Liabilitas terhadap Aset
Liability to Assets Ratio (%) 94,37 74,73 74,88 63,51 65,57
Rasio Aktivitas Activity Ratio
Tingkat Perputaran Persediaan Inventory Turnover Rate (x)
4,69 8,70 11,71 7,48 6,78
Tingkat Perputaran Aset 0,75 1,44 1,10 0,96 1,10
Grafik Keuangan Penting
Key Financial Charts
2022
2022
2022
2022 2018
2018
2018
2018 2019
2019
2019
2019 2020
2020
2020
2020 2021
2021
2021
2021
dalam jutaan Rupiah | in million Rupiah
dalam jutaan Rupiah | in million Rupiah
dalam jutaan Rupiah | in million Rupiah
dalam jutaan Rupiah | in million Rupiah
dalam jutaan Rupiah | in million Rupiah
Jumlah Aset
Total Assets
Jumlah Ekuitas
Total Equity
Jumlah Liabilitas
Total Liabilities
Penjualan Bersih
Net Sales
Laba (Rugi) Tahun Berjalan
Profit (Loss) for the Year
1.442.350
496.647
945.704
1.592.980
7.962 30
1.534.000
86.348
1.447.651
1.144.108 1.713.334
430.326
1.283.008
1.715.588 1.383.935
504.935
878.999
1.359.175 2.011.879
508.309
1.503.569
2.901.987
2022
2022
2022
2022 2018
2018
2018
2018 2019
2019
2019
2019 2020
2020
2020
2020 2021
2021
2021
2021
dalam persen | in percent dalam persen | in percent
dalam persen | in percent
dalam persen | in percent dalam persen | in percent
dalam persen | in percent
Rasio Lancar
Current Ratio
Rasio Liabilitas terhadap Ekuitas
Liability to Equity Ratio
Marjin Laba Bruto
Gross Profit Margin
Rasio Kas
Cash Ratio
Rasio Liabilitas terhadap Aset
Liability to Assets Ratio
Marjin Laba Bersih
Net Profit Margin
104,87
190,42
65,57 63,51
74,88 74,73
94,37
174,08 298,15
15,63
18,90 135,61 135,04
188,08
295,80 1.676,51
36,43 34,34
87,65 27,38
Uraian Description
Satuan
Unit 2022 2021 2020
ObatDrug
● Volume Produksi
Production Volume Unit
Unit
455.705.337 552.843.558 585.675.712
● Jumlah Produk yang telah mendapatkan Nomor Izin Edar (NIE) Total Products with Marketing Authorization (NIE)
Izin Edar Marketing Authorization
236 240 222
Alat Kesehatan dan Produk Lainnya Medical Devices and Other Products
● Volume Produksi Production Volume
Unit Unit
90.350 5.000.632 1.387.051
● Jumlah Produk yang telah mendapatkan NIE
Total Products with Marketing Authorization (NIE)
Izin Edar Marketing Authorization
105 107 106
Ikhtisar Saham
Share Highlights
Kinerja Saham Indofarma Tahun 2021-2022
2021-2022 Indofarma Share Performance
Kode Saham : INAF
Bursa Perdagangan Saham : Bursa Efek Indonesia
Periode Period
Jumlah Saham Beredar (lembar)
Outstanding Shares
Harga Saham Tertinggi Highest Share
Price
Harga Saham Terendah Lowest Share Price
Harga Saham Penutupan Closing Share
Price
Volume Perdagangan Trading Volume 2022
Triwulan Quarter I
3.099.267.500 2.400 1.620 1.630 217.000
Triwulan 3.099.267.500 2.400 995 1.005 40.800
Ticker Code : INAF
Stock Exchange : Indonesia Stock Exchange
Ikhtisar Kinerja Operasional
Operational Performance Highlights
Periode Period
Jumlah Saham Beredar (lembar)
Outstanding Shares
Harga Saham Tertinggi Highest Share
Price
Harga Saham Terendah Lowest Share Price
Harga Saham Penutupan Closing Share
Price
Volume Perdagangan Trading Volume 2021
Triwulan
Quarter I 3.099.267.500 4.833 2.743 2.917 522.652
Triwulan
Quarter I 3.099.267.500 2.767 2.093 2.560 107.162
Triwulan
Quarter III 3.099.267.500 2.907 2.377 2.440 99.483
Triwulan Quarter IV
3.099.267.500 2.593 2.247 2.380 63.072
Aksi Korporasi
Corporate Action
Sepanjang 2022, Perseroan tidak melakukan aksi korporasi saham baik berupa pemecahan saham (stock split), penggabungan saham (reverse stock), maupun perubahan nilai saham. Sehingga informasi tersebut tidak diungkapkan dalam Laporan Tahunan ini.
Informasi Penghentian Sementara dan/atau Sanksi Perdagangan Saham INAF
Information on Suspension and/or Trade Sanction of INAF Shares
Throughout 2022, the Company did not perform stock corporate actions in the forms of stock split, reverse stock or change in share value. Thus, such information is not disclosed in this Annual Report.
Hingga akhir Desember 2022, Perseroan tidak menerbitkan obligasi, sukuk, maupun obligasi konversi di bursa efek manapun. Selain itu, tidak terdapat obligasi, sukuk, maupun obligasi konversi Perusahaan yang jatuh tempo di tahun buku. Uraian lengkap mengenai Obligasi, Sukuk, dan/atau Obligasi Konversi yang pernah dicatatkan Perusahaan dapat dilihat pada bagian Kronologi Penerbitan dan/atau Pencatatan Efek Lainnya pada bab Profil Perusahaan dalam Laporan Tahunan ini.
Informasi Sumber Pendanaan Lainnya
Information on Other Financing Sources
Perseroan tidak memiliki sumber pendanaan lainnya pada tahun buku 2022 selain yang telah diungkapkan di dalam Laporan Tahunan ini.
As of the end of December 2022, the Company did not issue any Bonds, Sukuk, or Convertible Bonds on any stock exchange. In addition, there were no Bonds, Sukuk, or Convertible Bonds of the Company that mature in the fiscal year. A complete description of the Bonds, Sukuk and/or Convertible Bonds that have been listed by the Company can be seen in the Chronology of Issuance and/or Listing of Other Securities in the Company Profile chapter in this Annual Report.
The Company did not have other financing sources for the 2022 financial year other than those stated within this Annual Report.
Ikhtisar Obligasi, Sukuk, dan/atau Obligasi Konversi
Bonds, Sukuk and/or Convertible Bonds Overview
Penghargaan
Awards
CamScanner CamScanner
Thursday, September 29th2022 Jakarta
Muhamad IhsanCEO & Chief Editor Warta Ekonomi proudly honors:
as
Best TJSL 2022 with Outstanding Initiatives of Community Development Programs
Category: Healthcare PT Indofarma Tbk
Thursday, September 29th2022 Jakarta
Muhamad IhsanCEO & Chief Editor Warta Ekonomi proudly honors:
as
Best TJSL 2022 with Outstanding Initiatives of Community Development Programs
Category: Healthcare PT Indofarma Tbk
Top 50 Mid-Capitalization Public Listed Company Penghargaan yang digelar oleh Indonesia Institute for Corporate Directorship (IICD) dan BeritaSatu Media Holdings. Indofarma mendapat IICD Corporate Governance (CG) Award 2022 sebagai perusahaan yang memiliki praktik tata kelola terbaik dengan senantiasa mengimplementasikan lima prinsip Good Corporate Governance (GCG), yaitu keterbukaan, akuntabilitas, pertanggungjawaban, independensi, serta kewajaran dan kesetaraan.
The award was held by the Indonesia Institute for Corporate Directorship (IICD) and BeritaSatu Media Holdings. Indofarma received the IICD Corporate Governance (CG) Award 2022 as a company that runs the best governance practices by continuously implementing the five principles of Good Corporate Governance (GCG), namely transparency, accountability, responsibility, independence, and fairness and equality.
Holding BUMN Farmasi (Bio Farma, Kimia Farma dan Indofarma) mendapatkan anugerah AKHLAK Award 2, dari Kementerian BUMN, pada acara Refleksi 2 Tahun AKHLAK BUMN-AKHLAK Award 2022 pada tanggal 5 Juli 2022.
Bio Farma mendapatkan penghargaan Award AKHLAK 2 dalam kategori AKHLAK Award 2 Klaster Industri Kesehatan dan Akhlak Award 2 untuk BUMN Kompeten, sedangkan Kimia Farma dan Indofarma mendapatkan penghargaan kategori Indeks Implementasi AKHLAK Klaster Industri Kesehatan.
BUMN Pharmaceutical Holdings (Bio Farma, Kimia Farma and Indofarma) received AKHLAK Award 2, from the Ministry of SOE, at the 2 Year AKHLAK BUMN- AKHLAK Award 2022 Reflection event on July 5, 2022.
Bio Farma received an AKHLAK Award 2 in the AKHLAK Award 2 category for the Health Industry Cluster and Morals Award 2 for Competent SOEs, while Kimia Farma and Indofarma received an award for the AKHLAK Implementation Index category for the Health Industry Cluster.
Certificate of Appreciation for Establishing Business Responsibility Based on Sustainable Development Goals
Penghaargaan Best TJSL 2022 with outstanding Initiatives of Community Development Program, Category : Healthcare yang diperoleh dari Warta Ekonomi.co.id Research and Consulting
Best Corporate Social and Environmental Responsibility (CSER) 2022 Award with outstanding Initiatives of Community Development Program, Category : Healthcare obtained from Warta Ekonomi.co.id Research and Consulting
27 Mei 2022 | May 27, 2022 5 Juli 2022 | July 5, 2022 29 September 2022 | September 29, 2022
Peristiwa Penting
Significant Event
Rapat Kerja Nasional Indofarma Group 2022 Indofarma Group National Working Meeting 2022 PT Indofarma Tbk bersama dengan PT Indofarma Global Medika dan PT Farmalab Indo Utama mengadakan acara Rapat Kerja Nasional Indofarma Group 2022 (RAKERNAS) dengan tema: “Transformasi–
Menuju Indofarma Group yang Berdaya Saing dan Berkelanjutan”
Acara yang berlangsung selama 3 hari ini dihadiri oleh seluruh Jajaran Direksi dan Dewan Komisaris dari masing-masing entitas Perusahaan Indofarma Group.
Bapak Arief Pramuhanto sebagai Direktur Utama PT Indofarma Tbk membuka acara RAKERNAS sekaligus menyampaikan bahwa Sinergi Indofarma Group harus selalu memberikan kontribusi kepada negeri untuk memajukan Farmasi dan Alat Kesehatan di Indonesia.
PT Indofarma Tbk together with PT Indofarma Global Medika and PT Farmalab Indo Utama held the 2022 Indofarma Group National Working Meeting (RAKERNAS) with the theme: "Transformation - Towards a Competitive and Sustainable Indofarma Group"
The event which lasted for 3 days was attended by the entire Board of Directors and Board of Commissioners of each Indofarma Group Company entity. Mr. Arief Pramuhanto as President Director of PT Indofarma Tbk opened the RAKERNAS event as well as said that Indofarma Group Synergy must always contribute to the country to advance Pharmacy and Medical Devices in Indonesia.
Penandatanganan Pakta Integritas oleh Tim Pengamanan Pembangunan Strategis Signing of the Integrity Pact by the Strategic Development Security Team
Penandatanganan pakta intergritas oleh tim Pengamanan Pembangunan Strategis dalam kegiatan pengawalan dan pengamanan pelaksanaan proyek strategis Kementerian kesehatan dan non Kementerian kesehatan tahun 2022 di PT Indofarma Tbk. Dihadiri oleh Direksi PT Indofarma Tbk, Direksi PT Indofarma Global Medika dan Direksi PT Farmalab Indoutama dengan JAMINTEL Kejaksaan Agung.
Signing of the integrity pact by the Strategic Development Security team in escorting and securing the implementation of the Ministry of Health and non- Ministry of Health strategic projects in 2022 at PT Indofarma Tbk. Attended by the Directors of PT Indofarma Tbk, Directors of PT Indofarma Global Medika and Directors of PT Farmalab Indoutama with JAMINTEL Attorney General.
Januari | January 2022 Februari | February 2022
Bogor Jakarta
18-20 19
Penandatanganan Kesepakatan Bersama antara Pemerintah Kota Surakarta dan PT Indofarma Tbk Signing of the Joint Agreement between the City Government of Surakarta and PT Indofarma Tbk Penandatanganan Kesepakatan Bersama antara Pemerintah Kota Surakarta dan PT Indofarma Tbk tentang Pengembangan Ekosistem Herbal dan Alat Kesehatan di Kota Surakarta.
Signing of a Joint Agreement between the City Government of Surakarta and PT Indofarma Tbk regarding the Development of an Ecosystem of Herbs and Medical Devices in Surakarta City.
Penandatanganan Kerjasama Antara Poltekkes Kemenkes Jakarta II dengan PT Indofarma Tbk Signing of Collaboration Between Poltekkes Kemenkes Jakarta II and PT Indofarma Tbk Kerjasama ini merupakan langkah lanjut Hilirisasi alat timbang bayi berbasis digital (Digital Baby Scale) SMART-JBS Jakadu.
This collaboration is a further step in the down streaming of the SMART-JBS Jakadu (Digital Baby Scale).
Kick Off Pilot Project Telemedicine Kick Off of Telemedicine Pilot Project
PT Indofarma Tbk dan Kementerian Kesehatan RI telah melaksanakan Kick Off Pilot Project Telemedicine untuk di 10 lokasi di Indonesia.
PT Indofarma Tbk and the Indonesian Ministry of Health have implemented a Telemedicine Kick Off
Maret | March 2022 April | April 2022
Mei | May 2022 Surakarta
Jakarta
Jakarta
25 25
21
RUPST 2021 2021 AGMS
Bertempat di Ballroom A Hotel Borobudur - Jakarta, Perseroan telah menyelenggarakan RUPS Tahunan Tahun Buku 2021 pada tanggal 31 Mei 2022. RUPS tersebut dihadiri oleh seluruh anggota Dewan Komisaris dan Direksi, serta para Pemegang Saham Perseroan.
Dalam RUPS telah diambil keputusan atas 8 (delapan) Mata Acara, antara lain Perubahan Anggaran Dasar dan Perubahan Susunan Pengurus Perseroan.
Taking place at Ballroom A Hotel Borobudur - Jakarta, the Company has conducted the 2021 Annual GMS on May 31, 2022. The GMS was attended by all members of the Board of Commissioners and Directors, as well as the Company's Shareholders. The GMS has made decisions on 8 (eight) agenda items, including amendments to the Articles of Association and changes to the composition of the Company's management.
Public Expose Public Expose
Perseroan telah melaksanakan Paparan Publik secara daring pada tanggal 31 Mei 2022 Pukul 13.00-14.00 WIB. Paparan Publik dihadiri oleh Direktur Utama, Direktur Produksi dan Supply Chain, dan Corporate Secretary PT Indofarma serta 15 (lima belas) media.
Dalam Paparan Publik tersebut disampaikan Kinerja Perseroan Tahun 2021 dan Prospek Perseroan Tahun 2022.
The Company has carried out an online Public Expose on May 31 2022 at 13.00-14.00 WIB. The Public Expose was attended by the President Director, Director of Production and Supply Chain, and Corporate Secretary of PT Indofarma and 15 (fifteen) media. The Public Expose presented the Company's Performance for 2021 and the Company's Prospects for 2022.
Mei | May 2022 Mei | May 2022
31 31
Jakarta Jakarta
Robotic Telesurgery Robotic Telesurgery
Perseroan bersama dengan Rumah Sakit Umum Pusat (RSUP) Dr. Sardjito Yogyakarta dan Rumah Sakit Umum Pusat (RSUP) Dr. Hasan Sadikin Bandung telah berhasil melakukan program training untuk dokter bedah dan dokter residen di dua lokasi pilot projek tersebut.
Perseroan terlibat aktif dalam penyusunan kurikulum Pelatihan VR Simulator Robotic Telesurgery bagi Dokter di Rumah Sakit yang disahkan pada bulan Juni 2022 oleh Direktur Peningkatan Mutu Tenaga Kesehatan Kementerian Kesehatan RI.
The Company together with the Central General Hospital (RSUP) Dr. Sardjito Yogyakarta and the Central General Hospital (RSUP) Dr. Hasan Sadikin Bandung has successfully conducted a training program for surgeons and resident doctors at the two pilot project locations.
The Company is actively involved in preparing the VR Simulator Robotic Telesurgery Training curriculum for Doctors in Hospitals which was approved in June 2022 by the Director of Quality Improvement for Health Workers, Ministry of Health, Republic of Indonesia.
Komitmen dukungan IEBA kepada UMKM Obat Tradisional dan Virtual Expo Ekstrak Bahan Alam IEBA's commitment to support Traditional
Medicine MSMEs and Virtual Expo Natural Extracts Kegiatan ini dilaksanakan di Hotel Best Western Premier Solo Baru. Kegiatan ini sebagai upaya perseroan berpartisipasi bersama BPOM dalam peningkatan mutu, ketersediaan dan daya saing produk
This activity was held at the Best Western Premier Solo Baru Hotel. This activity is part of the company's efforts to participate with BPOM in improving product quality, availability and competitiveness
Juni | June 2022
04
Agustus | August 2022Sukoharjo Bandung dan Jakarta
Penandatanganan Nota Kesepahaman antara PT Indofarma Tbk dan PT Asuransi Perisai Listrik Nasional
Signing of a Memorandum of Understanding between PT Indofarma Tbk and PT Asuransi Perisai Listrik Nasional
Penandatanganan Nota Kesepahaman antara PT Indofarma Tbk dan PT Asuransi Perisai Listrik Nasional tentang Kerja Sama Penyediaan Katalog Dan Distribusi Produk Farmasi Dan Alat Kesehatan yang terkait dengan Penyelenggaraan Asuransi Kecelakaan, Administration Services Only (ASO) atau Third Party Administration (TPA), Asuransi Kesehatan dan Produk Asuransi Umum.
Signing of a Memorandum of Understanding between PT Indofarma Tbk and PT Asuransi Perisai Listrik Nasional concerning Cooperation in the Provision of Catalogs and Distribution of Pharmaceutical Products and Medical Devices related to the Implementation of Accident Insurance, Administration Services Only (ASO) or Third Party Administration (TPA), Health Insurance and Products General insurance.
Supply Chain Financing Supply Chain Financing
PT Indofarma Tbk dan Bank Rakyat Indonesia (BRI), menandatangani perjanjian pemberian fasilitas Supply Chain Financing Account Receivable Partnership.
PT Indofarma Tbk and Bank Rakyat Indonesia (BRI), signed an agreement to provide Supply Chain Financing Account Receivable Partnership facilities.
September | September 2022 September | September 2022
01 02
Jakarta Jakarta
Penandatanganan Joint Procurement Tahun 2022 antara Bio Farma, Kimia Farma, Indofarma dan Inuki
Signing of the 2022 Joint Procurement between Bio Farma, Kimia Farma, Indofarma and Inuki Kerja sama tersebut dalam rangka peningkatan proses pengadaan barang/jasa yang lebih efektif, efisien, transparan, akuntabel, dan pemenuhan Key Performance Indicator (KPI) untuk pengadaan barang/
jasa di Holding BUMN Farmasi.
This cooperation is in the context of improving the process of procuring goods/services that is more effective, efficient, transparent, accountable, and fulfilling the Key Performance Indicator (KPI) for the procurement of goods/services in the Holding of Pharmaceutical SOEs.
Penandatanganan Nota Kesepahaman antara PT Indofarma Tbk dengan PT Revass Utama Medika Signing of a Memorandum of Understanding between PT Indofarma Tbk and PT Revass Utama Medika
Bertempat di kantor marketing PT Indofarma Tbk, Jakarta Timur telah dilakukan penandatanganan Nota Kesepahaman antara PT Indofarma Tbk dengan PT Revass Utama Medika tentang Kerja Sama Pengembangan Produk Stent Jantung, Balon Kateter, dan produk angiografi lainnya.
Taking place at the marketing office of PT Indofarma Tbk, East Jakarta, a Memorandum of Understanding was signed between PT Indofarma Tbk and PT Revass Utama Medika regarding Cooperation in the Development of Cardiac Stent Products, Catheter Balloons, and other angiography products.
September | September 2022 September | September 2022
09 26
Jakarta Jakarta
Penerimaan Penghargaan Top Brand Award (TBA) Receiving the Top Brand Award (TBA)
Oktober | October 2022
20
Jakarta
Laporan Manajemen
Management Report
Laporan Dewan Komisaris
The Board of Commissioners’ Report
Para Pemegang Saham dan Pemangku Kepentingan yang Terhormat,
Puji dan syukur kami panjatkan ke hadirat Tuhan Yang Maha Esa, karena berkat rahmat dan karunia- Nya, PT Indofarma masih mampu melanjutkan perjalanan bisnis pada tahun 2022 dalam situasi yang penuh dinamika. Dewan Komisaris memberi apresiasi atas kerja keras jajaran Direksi dalam upaya menghadapi tantangan tersebut.
Pada kesempatan ini, izinkan kami selaku jajaran Dewan Komisaris Indofarma menyampaikan laporan pengawasan terhadap kinerja Perseroan selama tahun buku 2022 yang berisi tentang rincian pelaksanaan tugas pengawasan implementasi strategi dan pengelolaan bisnis serta pemberian nasihat kepada Direksi. Laporan ini menunjukkan akuntabilitas Dewan Komisaris dalam menjalankan fungsi pengawasan untuk menjaga agar kegiatan bisnis Perseroan dilaksanakan sesuai dengan tujuan, visi dan misi, Anggaran Dasar PT Indofarma serta peraturan perundang-undangan yang berlaku.
Kondisi Perekonomian Global dan Nasional
Perlambatan perekonomian global tahun 2022 masih mengalami tantangan besar. Hal ini tidak lepas dari situasi politik dan ekonomi yang mengakibatkan inflasi meningkat. Perekonomian Amerika Serikat (AS) hanya tumbuh 2,0%. Secara kumulatif mulai dari Maret sampai dengan Desember 2022 The Fed menaikkan suku bunga hingga 425 basis point (bps)
Dear Shareholders and Stakeholders,
Praise and thanks be to God Almighty, for His grace and mercy, PT Indofarma is still able to maintain its business journey in 2022 amidst a dynamic situation.
The Board of Commissioners appreciates the hard work of the Board of Directors in facing these challenges.
On this occasion, please allow us as the Board of Commissioners of Indofarma to present the supervisory report on the Company's performance during the fiscal year 2022, which contains details of the supervision of strategy implementation and business management as well as advisory to the Board of Directors. This report demonstrates the accountability of the Board of Commissioners in carrying out its supervisory function to ensure that the Company's business activities are carried out in accordance with the objectives, vision and mission, Articles of Association of PT Indofarma and prevailing laws and regulations.
Global and National Economic Conditions
The global economy in 2022 is still experiencing major challenges, related to the political and economic situation which has resulted in increased inflation.
The United States (US) economy only grew by 2.0%.
Cumulatively from March to December 2022, the Fed raised interest rates by 425 basis points (bps) to 4.25%
by the end of 2022.
Secara sektoral Badan Pusat Statistik (BPS) mencatat, Produk Domestik Bruto (PDB) Atas Dasar Harga Konstan (ADHK) industri kimia, farmasi, dan obat tradisional sebesar Rp235,48 triliun pada 2022. Nilai tersebut naik 0,69% dibandingkan pada tahun sebelumnya yaitu Rp233,87 triliun. Jika dibandingkan tahun 2021 yang mencapai 9,61%, pertumbuhan tersebut mengalami perlambatan secara signifikan.
Melambatnya pertumbuhan kinerja industri farmasi seiring dengan melandainya pandemi COVID-19 di dalam negeri.
Keberhasilan penanganan COVID- 19 di tahun 2022 ternyata lebih cepat dari yang diproyeksikan Perseroan.
Hal ini berdampak pada tidak optimalnya serapan produk penanganan COVID- 19 dan menimbulkan risiko penumpukan stok produk COVID- 19.
Penilaian Atas Kinerja Direksi
Pelaksanaan tugas, fungsi dan peran Dewan Komisaris didasarkan pada Board Manual (Charter Dewan Komisaris dan Charter Direksi) yang telah diperbarui dan disahkan pada 31 Desember 2021.
Penilaian Dewan Komisaris terhadap kinerja Direksi didasarkan pada pencapaian Key Performance Indicators (KPI) Direksi secara Individu, serta KPI Direksi secara kolegial yang dinilai oleh Pemegang Saham melalui mekanisme Rapat Umum Pemegang Saham (RUPS).
Terlepas dari segala tantangan yang ada, Dewan Komisaris menilai bahwa kinerja Direksi sepanjang
The Central Statistics Agency (BPS) recorded that the Gross Domestic Product (GDP) at constant prices (ADHK) of the chemical, pharmaceutical and traditional medicine industries amounted to Rp235.48 trillion in 2022. This value increased by 0.69% compared to the previous year, which was Rp233.87 trillion.
When compared to 2021, which reached 9.61%, this growth has slowed down significantly. The slowing growth in the performance of the pharmaceutical industry is in line with the passing of the COVID-19 pandemic in the country.
The successful handling of COVID- 19 in 2022 turned out to be faster than projected by the Company. This has an impact on the non-optimal uptake of COVID- 19 handling products and creates a risk of accumulation of COVID- 19 product stocks.
Assessment of the Performance of the Board of Directors
The implementation of the duties, functions and roles of the Board of Commissioners is based on the Board Manual (Charter of the Board of Commissioners and Charter of the Board of Directors) which has been updated and ratified on December 31, 2021.
The Board of Commissioners' assessment of the performance of the Board of Directors is based on the achievement of the Key Performance Indicators (KPI) of the Board of Directors individually, as well as the KPI of the Board of Directors collegially assessed by the Shareholders through the mechanism of the General Meeting of Shareholders (GMS).
Despite all the challenges, the Board of Commissioners considers that the performance of the Board of
Pada tahun 2022 realisasi nilai penjualan bersih sebesar Rp1,08 triliun turun dibanding dengan nilai penjualan bersih tahun 2021 sebesar Rp 1,84 triliun, dan Ebitda turun dari Rp184,56 miliar menjadi (Rp350,96) miliar pada tahun 2022 atau turun sebesar 290,16%.
Namun demikian, Dewan Komisaris bisa memahami situasi sulit yang dihadapi jajaran Direksi dan sangat mengapresiasi langkah-langkah yang dilakukan Direksi dalam mengatasi tantangan yang dihadapi Perseroan. Dewan Komisaris meyakini bahwa Direksi mampu bertindak lebih lincah dan responsif dalam melihat perubahan dan tantangan tersebut.
Ke depannya, sesuai dengan fungsi dan tanggung jawabnya, Dewan Komisaris tidak akan pernah jemu memberi saran, masukan bahkan peringatan dini untuk menghindari dampak krisis likuiditas. Dewan Komisaris juga akan memberi masukan agar sistem pengandalian dan kontrol yang dilakukan oleh Direksi dapat berjalan sebagaimana mestinya.
Pelaksanaan Tugas Dewan Komisaris
Dalam melaksanakan tugas fungsi pengawasan, Dewan Komisaris mengacu pada Anggaran Dasar PT Indofarma Tbk dan menerima masukan dari Komite Audit, Komite GCG dan Pemantauan Risiko, serta Komite Nominasi dan Remunerasi.
Dewan Komisaris selalu menerapkan mekanisme check and balances dengan tujuan untuk mencapai peningkatan kinerja Perseroan. Dalam melakukan
In 2022, the realization of net sales value of Rp1.08 trillion decreased compared to the net sales value in 2021 of Rp 1.84 trillion, and EBITDA decreased from Rp184.56 billion to (Rp350.96) billion in 2022 or a decrease of 290.16%.
However, whilst the Board of Commissioners understands the difficult situation faced by the Board of Directors, it appreciates the steps taken by the Board of Directors in overcoming the challenges faced by the Company. The Board of Commissioners believes that the Board of Directors is able to act more agile and responsive in seeing these changes and challenges.
Going forward, in accordance with its functions and responsibilities, the Board of Commissioners will never tire of providing advice, input and even early warnings to avoid the impact of the liquidity crisis. The Board of Commissioners will also provide input so as to the control system carried out by the Board of Directors can run properly.
Implementation of the Duties of the Board of Commissioners
In performing its supervisory function, the Board of Commissioners refers to the Articles of Association of PT Indofarma Tbk and receives input from the Audit Committee, GCG and Risk Monitoring Committee, and Nomination and Remuneration Committee.
The Board of Commissioners always implements a check and balances mechanism with the aim of achieving improved Company performance. In
Dewan Komisaris juga memantau kinerja Perseroan melalui penelaahan terhadap laporan-laporan yang disampaikan oleh Direksi secara berkala. Selain melakukan rapat internal, Dewan Komisaris senantiasa berupaya menjaga koordinasi yang baik dengan jajaran Direksi, salah satunya melalui forum rapat koordinasi gabungan bersama jajaran Direksi.
Sepanjang tahun 2022 Dewan Komisaris telah mengirimkan sejumlah surat, baik kepada jajaran Direksi maupun kepada Pemegang Saham Hal ini dilakukan setelah Dewan Komisaris melihat kinerja Perseroan yang terus menurun. Dewan Komisaris juga menginisiasi digelarnya Rapat Umum Pemegang Saham (RUPS) Luar Biasa pada bulan Januari 2023.
Dewan Komisaris telah melakukan rapat internal sebanyak 12(dua belas) kali dan rapat gabungan 16 (enam belas) kali. Melalui mekanisme rapat tersebut Dewan Komisaris memberikan pandangan dan saran sesuai dengan tugas pengawasan. Dengan demikian secara umum, Dewan Komisaris telah melakukan tugas pengawasan dengan baik.
Pandangan terhadap pelaksanaan GCG
Dewan Komisaris menyadari pentingnya pelaksanaan penerapan prinsip Tata Kelola Perusahaan yang Baik atau Good Corporate Governance (GCG). Dewan Komisaris tidak pernah jemu mengingatkan kepada jajaran direksi untuk selalu menerapkan praktik-praktik GCG secara konsisten.
Dewan Komisaris secara reguler menerima laporan dari Komite GCG terkait pelaksanaan prinsip-prinsip GCG oleh Perseroan. Berdasarkan laporan tersebut Dewan Komisaris memberi arahan dan masukan
The Board of Commissioners also monitors the Company's performance through the review of reports submitted by the Board of Directors on a regular basis. In addition to conducting internal meetings, the Board of Commissioners always strives to maintain good coordination with the Board of Directors, one of which is through a joint coordination meeting forum with the Board of Directors. Throughout 2022 the Board of Commissioners has sent a number of letters, both to the Board of Directors and to the Shareholders. This was done after the Board of Commissioners saw the Company's performance which continued to decline. The Board of Commissioners also initiated an Extraordinary General Meeting of Shareholders (GMS) in January 2023.
Board of Commissioners held 12 (twelve) internal meetings and 16 (sixteen) joint meetings. Through the meeting mechanism, the Board of Commissioners provided views and suggestions in accordance with its supervisory duties. Thus in general, the Board of Commissioners has performed its supervisory duties well.
Views on the implementation of GCG
The Board of Commissioners realizes the importance of implementing the principles of Good Corporate Governance (GCG). The Board of Commissioners never fails to remind the Board of Directors to consistently implement GCG practices.
The Board of Commissioners regularly receives reports from the GCG Committee regarding the implementation of GCG principles by the Company. Based on these reports, the Board of Commissioners provides direction
diharapkan dapat mendorong semangat Insan Indofarma untuk meningkatkan kualitas penerapan GCG dan menegakkan budaya anti-korupsi, anti suap, dan anti fraud dalam rangka mewujudkan budaya korporasi yang bersih, sehat, jujur, dan adil.
Penilaian terhadap Kinerja Komite di Bawah Dewan Komisaris
Dalam melakukan pengawasan atas Perseroan, Dewan Komisaris dibantu oleh 3 (tiga) yaitu Komite Audit, Komite GCG dan Pemantauan Risiko, serta Komite Nominasi dan Remunerasi. Secara umum Dewan Komisaris menilai seluruh program kerja Komite sebagaimana tercantum dalam Rencana Kerja tiap Komite di 2022, telah terealisasi dan berjalan dengan baik. Dewan Komisaris menerima seluruh rekomendasi dari setiap Komite. Rekomendasi tersebut menjadi bahan pertimbangan dalam proses pengambilan keputusan, usulan dan saran yang disampaikan kepada Direksi.
Dari aspek komunikasi, Komite melakukan komunikasi sangat intensif dengan Dewan Komisaris, terutama menyangkut isu utama yang terjadi dalam Perseroan.
Komite juga selalu menyampaikan progres tindak lanjut saran Dewan Komisaris yang telah dilakukan oleh Direksi.
Pandangan atas prospek usaha Perseroan yang disusun Direksi
achievement is expected to encourage the spirit of Indofarma personnel to improve the quality of GCG implementation and uphold an anti-corruption, anti-bribery, and anti-fraud culture in order to realize a clean, healthy, honest, and fair corporate culture.
Assessment of the Performance of Committees under the Board of Commissioners
In supervising the Company, the Board of Commissioners is assisted by 3 (three) Audit Committees, GCG and Risk Monitoring Committee, and Nomination and Remuneration Committee. In general, the Board of Commissioners assessed that all Committee work programs as stated in the Work Plan of each Committee in 2022, have been realized and run well. The Board of Commissioners received all recommendations from each Committee. These recommendations are taken into consideration in the decision-making process, proposals and suggestions submitted to the Board of Directors.
In terms of communication, the Committees communicate very intensively with the Board of Commissioners, especially regarding major issues that occur in the Company. The Committee also always conveys the progress of the follow-up of the Board of Commissioners' suggestions that have been carried out by the Board of Directors.
Outlook on the Company's business
prospects prepared by the Board of
peningkatan permintaan domestik, baik konsumsi rumah tangga maupun investasi. Prakiraan tersebut sejalan dengan naiknya mobilitas masyarakat pascapenghapusan kebijakan Pemberlakuan Pembatasan Kegiatan Masyarakat (PPKM), membaiknya prospek bisnis, meningkatnya aliran masuk Penanaman Modal Asing (PMA), serta berlanjutnya penyelesaian Proyek Strategis Nasional (PSN). Kementerian Perindustrian memproyeksikan industri farmasi diperkirakan tumbuh sekira 11,2%, lebih tinggi dari tahun 2022 yang sebesar 10,2%.
Melihat dinamika parameter tersebut, Dewan Komisaris merasa optimistis dengan rencana kerja 2023 yang telah disusun oleh Direksi terutama menyangkut kebijakan shifting strategy dan refocusing produk pada produk herbal dan medical device. PT Indofarma adalah satu-satunya BUMN yang bergerak di bidang alat kesehatan dan Dewan Komisaris melihat hal ini sebagai sebuah tantangan sekaligus peluang. Dewan Komisaris menyarankan agar Direksi berkolaborasi dengan Usaha Mikro, Kecil dan Menengah (UMKM) untuk produk yang bersifat massal.
Meski demikian Dewan Komisaris tetap memberi catatan atas rencana kerja Direksi tahun 2023. Dewan Komisaris meminta jajaran Direksi secara sungguh- sungguh dan hati-hati dalam melaksanakan rencana kerja tersebut. Dewan Komisaris juga senatiasa mengingatkan agar Perseroan selalu memperhitungkan risiko-risiko yang mungkin timbul dan mengedepankan GCG di tiap fase operasional.
Dewan Komisaris juga mendorong segera dilakukan privatisasi terhadap anak perusahaan yaitu PT Indofarma Global Medika (IGM) yang bergerak dalam bidang perdagangan dan distribusi produk
and investment. The forecast is in line with the increase in community mobility after the abolition of the Restrictions on Community Activities (PPKM) policy, improving business prospects, increasing inflows of Foreign Direct Investment (FDI), and the continued completion of the National Strategic Project (PSN).
The Ministry of Industry projects the pharmaceutical industry to grow by approximately 11.2%, higher than 2022's 10.2%.
Seeing the dynamics of these parameters, the Board of Commissioners feels optimistic about the 2023 work plan that has been prepared by the Board of Directors, especially regarding the policy of shifting strategy and refocusing products on herbal products and medical devices. PT Indofarma is the only state- owned enterprise engaged in medical devices and the Board of Commissioners sees this as both a challenge and an opportunity. The Board of Commissioners recommends that the Board of Directors collaborate with Micro, Small and Medium Enterprises (MSMEs) for bulk products.
However, the Board of Commissioners still gave notes on the Board of Directors' work plan for 2023. The Board of Commissioners asks the Board of Directors to be serious and careful in implementing the work plan. The Board of Commissioners also reminds the Company to always take into account the risks that may arise and prioritize GCG in every operational phase.
The Board of Commissioners also encourages the immediate privatization of its subsidiary, PT Indofarma Global Medika (IGM), which is engaged in the trading and distribution of pharmaceutical products.
Perubahan Komposisi Dewan Komisaris
Sepanjang tahun 2022, komposisi Dewan Komisaris Indofarma mengalami perubahan sebanyak 1 (satu) kali. Berdasarkan Keputusan RUPS Tahunan Tahun Buku 2021 yang dinyatakan dalam Akta Pernyataan Keputusan Rapat di hadapan Notaris M. Nova Faisal, S.H., M.Kn Nomor 04 tanggal 03 Juni 2022 Pemegang Saham mengangkat saudara Achmad Ghufron Sirodj sebagai Komisaris Independen. Dengan demikian susunan Dewan Komisaris Perseroan pada tahun buku 2022 adalah:
• Komisaris Utama : Laksono Trisnantoro
• Komisaris : Didi Agus Mintadi
• Komisaris Independen : Teddy Wibisana
• Komisaris Independen : Achmad Ghufron Sirodj.
Apresiasi
Saya bersama seluruh anggota Dewan Komisaris, mengucapkan terima kasih kepada seluruh jajaran Direksi yang telah bekerja keras agar Perseroan tetap berjalan dalam situasi yang penuh tantangan. Dewan Komisaris yakin dengan semangat dan komitmen yang kuat dari insan Indofarma, Perseroan akan tetap eksis.
Atas nama Dewan Komisaris, kami juga ingin menyampaikan rasa terima kasih kepada Pemegang Saham atas kepercayaan dan dukungannya. Hal itu menambah keyakinan kami bahwa Perseroan selalu optimistis menyambut masa depan yang lebih baik.
Changes in Board of Commissioners Composition
Throughout 2022, the composition of Indofarma's Board of Commissioners changed 1 (one) time. Based on the Resolution of the Annual GMS for Fiscal Year 2021 as stated in the Deed of Meeting Resolution before Notary M. Nova Faisal, S.H., M.Kn Number 04 dated June 03, 2022, the Shareholders appointed Achmad Ghufron Sirodj as Independent Commissioner.
Thus the composition of the Company's Board of Commissioners in the financial year 2022 is:
• President Commissioner : Laksono Trisnantoro
• Commissioner : Didi Agus Mintadi
• Independent Commissioner : Teddy Wibisana
• Independent Commissioner : Achmad Ghufron Sirodj.
Appreciation
I, along with all members of the Board of Commissioners, would like to thank the entire Board of Directors for their hard work in keeping the Company running in a challenging situation. The Board of Commissioners is confident that with the strong spirit and commitment of Indofarma's people, the Company will continue to exist.
On behalf of the Board of Commissioners, we would also like to express our gratitude to the Shareholders for their trust and support. It adds to our confidence that the Company is always optimistic for a better future.
Laporan Direksi
The Board of Directors’ Report
Para Pemegang Saham dan Pemangku Kepentingan yang Terhormat,
Pertama-tama, perkenankan kami memanjatkan puji dan syukur ke hadirat Tuhan yang Maha Kuasa atas limpahan karunia-Nya. Bagi Perseroan, tahun 2022 adalah tahun yang penuh dinamika.
Sebagai anak perusahaan holding Badan Usaha Milik Negara (BUMN) Farmasi, Indofarma senantiasa menjalankan penugasan dari Pemerintah dalam upaya mengatasi COVID-19, terutama dalam hal pengadaan obat dan alat kesehatan. Perseroan merasa bangga ikut mengambil peran dalam upaya Perintah menekan laju kasus COVID-19.
Tinjauan Makro Ekonomi dan Industri
Tahun 2022 dipenuhi dengan perubahan yang cepat dan tak terduga. Dipicu oleh ketegangan geopolitik antara Rusia dan Ukraina, dunia dihadapkan pada tantangan-tantangan baru yang memicu krisis energi global, kelangkaan pangan, dan tekanan inflasi. Inflasi di Uni Eropa mencapai 9,2% pada Desember 2022, sementara angka inflasi Amerika Serikat mencapai 9,1% pada Juni 2022. Dalam World Economic Outlook edisi Januari 2023, IMF memprediksi pertumbuhan ekonomi global tahun 2022 sebesar 3,4%.
Di sisi lain, upaya negara-negara dunia mengatasi pandemi COVID-19 mulai menunjukkan hasil. Hal ini terlihat dari mulai melandainya angka kasus COVID-19.
Namun belum tuntasnya pandemi masih memberi
Dear Shareholders and Stakeholders,
First of all, please allow us to offer our praise and gratitude to the Almighty God for His blessings. The Company views 2022 as a dynamic year.
As a subsidiary of the State-Owned Enterprises (SOEs) Pharmaceutical holding company, Indofarma is assigned by the Government to manage efforts to overcome the COVID-19 pandemic, especially in terms of medicine and medical equipment procurement.
The Company takes pride in participating in the Government's efforts to suppress the rate of COVID-19 cases.
Macroeconomic and Industry Overview
The year 2022 saw rapid and unpredictable changes.
Fueled by geopolitical tensions between Russia and Ukraine, the world was confronted with new challenges that triggered a global energy crisis, food shortages, and inflationary pressures. Inflation in the European Union reached 9.2% in December 2022, while the US inflation rate reached 9.1% in June 2022. In the January 2023 edition of the World Economic Outlook, the IMF forecasts global economic growth in 2022 at 3.4%.
On the other hand, the efforts of world countries to overcome the COVID-19 pandemic have begun to show results. This is evident from the decline in the number of COVID-19 cases. However, the pandemic
Rupiah terhadap Dolar Amerika Serikat terdepresiasi 8,45% dibandingkan dengan akhir tahun 2021 menjadi Rp15.568 per dolar Amerika Serikat.
Secara sektoral industri kimia, farmasi, dan obat tradisional tumbuh sebesar 0,69% dibanding tahun sebelumnya menjadi sebesar Rp235,48 triliun pada 2022. Pertumbuhan itu mengalami penurunan signifikan dibanding pertumbuhan tahun sebelumnya yang mencapai 9,61%.
Analisis terhadap kinerja Perseroan
Pada tahun 2022 kinerja Perseroan sangat dipengaruhi oleh melandainya angka kasus COVID-19 dan keberhasilan pemerintah mengendalikan pandemi dengan sangat cepat. Sebagai bagian dari tanggung jawab sosial Perseroan selaku garda depan bidang kesehatan, selama era COVID-19, Perseroan melakukan berbagai upaya strategi untuk mendukung pemerintah dalam penanganan pandemi terkait protokol serta pemenuhan obat dan alat kesehatan yang dibutuhkan.
Turbulensi selama tahun 2020 dan 2021, berdampak pada akumulasi jumlah persediaan Obat dan alat kesehatan hingga tahun 2022, disebabkan persediaan produk COVID-19 tidak lagi sesuai dengan kebutuhan pengobatan saat ini.
Kondisi tersebut pada akhirnya berpengaruh terhadap ketersediaan likuiditas akibat tertahannya modal kerja dalam persediaan dan tagihan kepada pelanggan, berujung pada ketidakmampuan Perseroan untuk mencapai target penjualan yang telah ditetapkan.
Pada tahun 2022, perolehan Laba (Rugi) Tahun Berjalan Perusahaan sebesar (Rp428,488 miliar), turun 1.040,47%
dibanding tahun 2021. Realisasi nilai penjualan bersih
Rupiah terhadap Dolar Amerika Serikat terdepresiasi 8,45% dibandingkan dengan akhir tahun 2021 menjadi Rp15.568 per dolar Amerika Serikat.
By sector, the chemical, pharmaceutical, and traditional medicine industries grew by 0.69% over the previous year to Rp235.48 trillion in 2022. This growth has decreased significantly compared to the previous year's growth of 9.61%.
Analysis of the Company's performance
The performance of the Company in 2022 is greatly influenced by the slowing down of the number of COVID-19 cases and the success of the government in controlling the pandemic very quickly. As the vanguard of the health sector, and also as part of its corporate social responsibility, the Company has made various strategic efforts to support the government in handling pandemics related to protocols and the fulfillment of medicines and medical devices needed. Turbulence during 2020 and 2021, had an impact on the accumulated amount of inventory of medicines and medical devices until 2022, due to the inventory of COVID-19 products no longer in accordance with current medical needs.
This condition ultimately affects the availability of liquidity due to the retention of working capital in inventory and bills to customers, leading to the Company's inability to achieve the sales targets that have been set.
In 2022, the Company's Profit (Loss) for the Year amounted to ( Rp428.488 billion), a decrease of
penjualan Obat tahun 2021 tersebut akibat penjualan vaksin yang tidak lagi dilakukan di tahun 2022.
Menghadapi situasi sulit tersebut Perseroan berupaya melakukan berbagai terobosan dengan melakukan efisiensi, termasuk menurunkan Beban Umum dan Beban Penjualan. Pada saat bersaman Direksi juga mengajukan restrukturisasi kepada perusahaan induk sebagai upaya penyelesaian masalah yang dihadapi Perseroan. Program restrukturisasi tersebut telah disetujui oleh Holding dan saat ini tengah berlangsung dengan beberapa aksi meliputi penyelesaian kewajiban masa lalu, dukungan finansial, restrukturisasi organisasi dan Human Capital, perubahan portfolio bisnis, serta optimalisasi aset.
Analisis Atas Prospek Usaha
Direksi menjadikan kondisi tahun 2022 sebagai base line untuk membangun kembali bisnis perseroan di tahun 2023 dalam semangat optimisme, dengan melihat peluang pasar bisnis healthcare yang terbuka luas dan potensi sumber daya yang dimiliki oleh perseroan .
Pada awal tahun 2023 Direksi menginisiasi perubahan strategi (shifting strategy) dengan mengubah cara pendekatan dari hanya Business to Consumer (B to C) menjadi Business to Business (B to B) dengan pola partnership dalam proses produksi dan pemasaran.
Strategi tersebut diharapkan dapat mengakselerasi performa bisnis Perseroan dalam volume yang lebih besar. Untuk mendukung hal tersebut diperlukan
at Rp2.040 trillion. The high sales of Medicines in 2021 were due to the sale of vaccines which were no longer carried out in 2022.
Facing this difficult situation, the Company is trying to make various breakthroughs by making efficiencies, including reducing General Expenses and Selling Expenses. At the same time, the Board of Directors also proposed restructuring to the parent company as an effort to resolve the problems faced by the Company. The restructuring program has been approved by the Holding and is currently underway with several actions including settlement of past liabilities, f inancial support, organizational restructuring and Human Capital, business portfolio changes, and asset optimization.
Analysis of Business Prospects
The Board of Directors made the condition in 2022 as a baseline to rebuild the Company's business in 2023 in the spirit of optimism, by looking at the wide open healthcare business market opportunities and the potential resources owned by the C
